Evaluation of MDM2 Regulation on AURKB Expression in Lung Cancer
Abstract
Objective. This study was conducted to analyze the molecular mechanism of the MDM2 regulation on AURKB in lung cancer cells. Background. Lung cancer is the leading cause of cancer death within the United States, with the 5-year survival rate at about 22%, indicating the need to develop different drugs and treatment strategies. This study focuses on understanding the mechanisms linking MDM2 and AURKB to develop new treatment strategies against lung cancer. Methods. The H446 cells were treated with RG7388 (2 μM), an MDM2 inhibitor, and Barasertib (50 nM), an AURKB inhibitor, including a combination of the two drugs for 24 hrs. After treatments, the cells were lysed, and western blots were performed for detecting the MDM2, AURKB, FOXO3a, AKT, p-AKT, and β-actin expression levels. The H460 and HCC827 cells are treated in the same manner with the drugs. Results. The H446 cells treated with RG7388 and exhibited downregulation of MDM2 and AURKB protein levels. In addition, the levels of p-AKT expression were also found to be in downregulation after RG7388 treatment. Conclusion. The collected data suggests that MDM2 inhibition by RG7388 leads to the down-regulation of AURKB expression. Also, downregulating AURKB can lead to the onset of cell cycle arrest and resultant cell death. Additional experimentation will be conducted using H460 and HCC827 cells to further evaluate the impact of RG7388 treatment on lung cancer cells. Grants. This study was funded by the PFRDG grant 334877 and the financial support from the Royal Dames of Cancer Research Inc., Ft. Lauderdale, Florida.
Faculty Sponsors
Dr. Appu Rathinavelu, Dr. Thiagarajan Venkatesan, Dr. Umamaheswari Natarajan, Dr. Katie Crump
Project Type
Event
Location
Alvin Sherman Library
Start Date
4-6-2022 12:00 PM
End Date
4-7-2022 5:00 PM
Evaluation of MDM2 Regulation on AURKB Expression in Lung Cancer
Alvin Sherman Library
Objective. This study was conducted to analyze the molecular mechanism of the MDM2 regulation on AURKB in lung cancer cells. Background. Lung cancer is the leading cause of cancer death within the United States, with the 5-year survival rate at about 22%, indicating the need to develop different drugs and treatment strategies. This study focuses on understanding the mechanisms linking MDM2 and AURKB to develop new treatment strategies against lung cancer. Methods. The H446 cells were treated with RG7388 (2 μM), an MDM2 inhibitor, and Barasertib (50 nM), an AURKB inhibitor, including a combination of the two drugs for 24 hrs. After treatments, the cells were lysed, and western blots were performed for detecting the MDM2, AURKB, FOXO3a, AKT, p-AKT, and β-actin expression levels. The H460 and HCC827 cells are treated in the same manner with the drugs. Results. The H446 cells treated with RG7388 and exhibited downregulation of MDM2 and AURKB protein levels. In addition, the levels of p-AKT expression were also found to be in downregulation after RG7388 treatment. Conclusion. The collected data suggests that MDM2 inhibition by RG7388 leads to the down-regulation of AURKB expression. Also, downregulating AURKB can lead to the onset of cell cycle arrest and resultant cell death. Additional experimentation will be conducted using H460 and HCC827 cells to further evaluate the impact of RG7388 treatment on lung cancer cells. Grants. This study was funded by the PFRDG grant 334877 and the financial support from the Royal Dames of Cancer Research Inc., Ft. Lauderdale, Florida.
